Articles tagged "Immunosuppression"

2020 American Transplant Congress
Early Steroid Withdrawal in HIV+ Kidney Transplant Recipients is Associated with Increased Acute Rejection by 1 Year
W. A. Werbel¹, S. Bae², S. Yu³, F. Al-Ammary⁴, C. M. Durand¹, D. L. Segev³
¹Infectious Diseases, Johns Hopkins University, Baltimore, MD, ²Epidemiology, Johns Hopkins University, Baltimore, MD, ³Surgery, Johns Hopkins University, Baltimore, MD, ⁴Nephrology, Johns Hopkins University, Baltimore, MD
*Purpose: Kidney transplantation among HIV+ recipients (HIV+ KT) is increasing, with excellent outcomes. Acute rejection (AR), however, is 2-3-fold more common than in HIV- KT.…
2020 American Transplant Congress
Risk of Tuberculosis in Kidney Transplantation Recipients Compared to Dialysis Patients or General Population: A Nationwide Cohort Study with Matched Controls
S. Park¹, J. Kim², M. Yu³, J. Lee², K. Han⁴, S. Park¹, Y. Kim², D. Kim², Y. Kim², H. Lee²
¹Armed Forces Capital Hospital, Seoul, Korea, Republic of, ²Seoul National University Hospital, Seoul, Korea, Republic of, ³Hanyang Guri Hospital, Gyeonggi-do, Korea, Republic of, ⁴Catholic University, College of Medicine, Seoul, Korea, Republic of
*Purpose: Risk of Mycobacterium tuberculosis (TB) infection has been reported to be increased in kidney transplant recipients. However, a nationwide cohort study from an Asian…
2020 American Transplant Congress
Early Calculation of the Tacrolimus Concentration-to-Dose Ratio Does Not Predict Outcomes after Renal Transplantation
K. Schütte-Nütgen, I. Bartmann, B. Suwelack, S. Reuter
Department of Internal Medicine D, University Hospital Münster, Münster, Germany
*Purpose: There is emerging interest in the concentration-to-dose (C/D) ratio of tacrolimus (Tac) as it is linked to outcomes after renal transplantation (RTx). Recently, we…
2020 American Transplant Congress
dd-cfDNA as a Risk Factor for Initiating De-Novo Donor Specific Antibodies in Heart Transplantation
E. DePasquale¹, J. Kobashigawa², S. Pinney³, K. Khush⁴
¹Keck Hospital of USC, Los Angeles, CA, ²Cedars-Sinai, Beverly Hills, CA, ³Mount Sinai Health System, New York, NY, ⁴Stanford University, Stanford, CA
*Purpose: We hypothesize that subclinical inflammation, resulting in molecular injury of the cardiac allograft, may contribute to sensitization of the recipients’ immune system. Antigenic presentation…
2020 American Transplant Congress
Outcomes of De Novo Belatacept-Based Immunosuppression in Recipients of Kidneys at High Risk for Delayed Graft Function in the Setting of Lymphocyte Depleting Immune Modulation
T. L. Shertel¹, M. A. Wynd¹, M. A. Pereiras¹, J. T. McKeen¹, Y. Y. Yushkov², B. R. Schleich³, S. E. Geatrakas², A. Patel², M. J. Goldstein²
¹Pharmacy, Hackensack University Medical Center, Hackensack, NJ, ²Organ Transplant, Hackensack University Medical Center, Hackensack, NJ, ³Patient Safety and Quality, Hackensack University Medical Center, Hackensack, NJ
*Purpose: Our center created an immunosuppression protocol using de novo belatacept (DNB) in the setting of lymphocyte depletion to increase the utilization of deceased donor…
2020 American Transplant Congress
Cross-Sectional Survey to Assess Barriers to Medication Adherence in an Urban Transplant Population
A. Reticker, B. Valdepenas, L. Glauner, O. Piatek, S. Kerns, P. West-Thielke
University of Illinois, Chicago, IL
*Purpose: Non-adherence is a strong predictor of post-transplant outcome. Barriers to medication adherence (MA) include the cost and complexity of a medication regimen, education level,…
2020 American Transplant Congress
Delayed Introduction of Mammalian Inhibitors of Rapamycin (mTOR) Post Kidney Transplantation Might Avoid the Chronic Nephrotoxicity of Calcineurin Inhibitors. Herein We Are Reporting an Eight-Years Single Center Experience of mTOR-Based Immunosuppression Regimen in Comparison with Cyclosporin-Based Regimen
W. A. Hassan¹, H. M. Tawfik²
¹Medicine-Nephrology, University of Tennessee Health Science Center, Memphis, TN, ²Medicine-Nephrology, Minia Nephrology Hospital, Minia University, Minia, Egypt
*Purpose: Delayed introduction of mTOR inhibitors post kidney transplantation might avoid the chronic nephrotoxicity of CNI: eight-years single center experience.*Methods: This is a retrospective analysis…
2020 American Transplant Congress
Is Azathioprine the Right Choice in De Novo Lung Transplantation?
A. Chan¹, B. Sirandas¹, A. Carlson¹, C. Truax¹, B. Clark¹, I. Hall², B. Cahill³, L. Smith¹
¹Pharmacy, University of Utah Health, Salt Lake City, UT, ²Nephrology, University of Utah Health, Salt Lake City, UT, ³Pulmonary, University of Utah Health, Salt Lake City, UT
*Purpose: The antiproliferative of choice in lung transplantation (LT) remains controversial. Limited data exists on azathioprine (AZA) dose reductions or the conversion of AZA to…
2020 American Transplant Congress
Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform
S. Berger¹, M. Bakr¹, F. Bemelman¹, R. Danguilan¹, H. De Fijter¹, D. Han¹, M. Kim¹, E. Mor¹, A. Patel¹, M. Hernandez Gutierrez², A. Gawai², Y. Watarai¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: To assess the efficacy and safety outcomes in de novo renal transplant (RTx) recipients receiving everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolate with…
2020 American Transplant Congress
Envarsus XR Use Can Benefit Serum Creatinine Levels in Vascularized Composite Allotransplantation Patients
C. M. Cooney¹, V. Javia¹, J. Littleton¹, D. S. Cooney¹, R. J. Redett¹, J. T. Shores¹, D. C. Brennan², G. Brandacher¹
¹Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Surgery, Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Vascularized composite allotransplantation (VCA) is a life-enhancing (as opposed to life-saving) procedure. Therefore, minimizing adverse outcomes associated with chronic immunosuppression is vital to determining…